- Home
- NPT vs IGC Comparison
NPT vs IGC Comparison
Compare NPT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | IGC |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 28.9M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NPT | IGC |
|---|---|---|
| Price | $1.31 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 58.2K | ★ 464.4K |
| Earning Date | 05-23-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $0.24 |
| 52 Week High | $22.38 | $0.50 |
Technical Indicators
Market Signals| Indicator | NPT | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 43.42 |
| Support Level | $1.19 | $0.28 |
| Resistance Level | $1.69 | $0.31 |
| Average True Range (ATR) | 0.13 | 0.01 |
| MACD | 0.24 | -0.00 |
| Stochastic Oscillator | 25.44 | 35.38 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.